DE60205872D1 - Oxindolderivate als cdk-1 inhibitoren und deren verwendung in therapie - Google Patents

Oxindolderivate als cdk-1 inhibitoren und deren verwendung in therapie

Info

Publication number
DE60205872D1
DE60205872D1 DE60205872T DE60205872T DE60205872D1 DE 60205872 D1 DE60205872 D1 DE 60205872D1 DE 60205872 T DE60205872 T DE 60205872T DE 60205872 T DE60205872 T DE 60205872T DE 60205872 D1 DE60205872 D1 DE 60205872D1
Authority
DE
Germany
Prior art keywords
compound
formula
alkyl
directed
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60205872T
Other languages
English (en)
Other versions
DE60205872T2 (de
Inventor
Jean-Francois Riou
Michel Maratrat
Lucile Grondard
Fabienne Thompson
Odile Petitgenet
Patrick Mailliet
Jacques Lavayre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE60205872D1 publication Critical patent/DE60205872D1/de
Application granted granted Critical
Publication of DE60205872T2 publication Critical patent/DE60205872T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
DE60205872T 2001-02-27 2002-02-25 Oxindolderivate als cdk-1 inhibitoren und deren verwendung in therapie Expired - Fee Related DE60205872T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0102624A FR2821358B1 (fr) 2001-02-27 2001-02-27 Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique
FR0102624 2001-02-27
PCT/FR2002/000681 WO2002068411A1 (fr) 2001-02-27 2002-02-25 Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique

Publications (2)

Publication Number Publication Date
DE60205872D1 true DE60205872D1 (de) 2005-10-06
DE60205872T2 DE60205872T2 (de) 2006-06-08

Family

ID=8860477

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60205872T Expired - Fee Related DE60205872T2 (de) 2001-02-27 2002-02-25 Oxindolderivate als cdk-1 inhibitoren und deren verwendung in therapie

Country Status (9)

Country Link
US (1) US20040110770A1 (de)
EP (1) EP1366038B1 (de)
AT (1) ATE303380T1 (de)
DE (1) DE60205872T2 (de)
DK (1) DK1366038T3 (de)
ES (1) ES2244751T3 (de)
FR (1) FR2821358B1 (de)
PT (1) PT1366038E (de)
WO (1) WO2002068411A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008775A (es) * 2007-02-13 2010-03-01 Schering Corp Agonistas de adrenorreceptores alfa2c funcionalmente selectivos.
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
CN102688234B (zh) * 2011-03-21 2015-07-29 华东理工大学 吲哚酮衍生物作为rsk2抑制剂的合成与应用
WO2016055454A1 (en) * 2014-10-06 2016-04-14 International Society For Drug Development S.R.L. Pharmaceutical combination for the treatment of tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
ES2239393T3 (es) * 1997-05-07 2005-09-16 Sugen, Inc. Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa.
US6316429B1 (en) * 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
ES2194468T3 (es) * 1998-05-29 2003-11-16 Centre Nat Rech Scient Uso de derivados del bisindol indigoide para la fabricacion de un medicamento para inhibir quinasas dependientes de ciclinas.
US6313310B1 (en) * 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles

Also Published As

Publication number Publication date
DK1366038T3 (da) 2005-12-19
ES2244751T3 (es) 2005-12-16
EP1366038A1 (de) 2003-12-03
WO2002068411A1 (fr) 2002-09-06
ATE303380T1 (de) 2005-09-15
US20040110770A1 (en) 2004-06-10
FR2821358B1 (fr) 2006-04-07
FR2821358A1 (fr) 2002-08-30
PT1366038E (pt) 2005-11-30
EP1366038B1 (de) 2005-08-31
DE60205872T2 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
NO20061194L (no) Mitotiske kinesininbibitorer
YU65502A (sh) Supstituisani beta-karbolini sa ikb-kinaza inhibirajućim dejstvom
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
HRP20050059B8 (hr) Novi inhibitori kinaza
YU84603A (sh) Novi inhibitori tirozin kinaze
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
NO20052578L (no) Kombinert administrering av et indolinon med et kjemoterapeutisk middel for celleproliferasjonslidelser
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
EP0954334A4 (de) Verwendung von Makrophagen-Wanderungs-inhibitorischen Faktor-Antagonisten zur Krebstherapie
TW200407311A (en) N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
EA201101326A1 (ru) Ингибиторы антиапоптотических белков на основе нафталина
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
GB0112348D0 (en) Compounds
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2022010512A (es) Inhibidores de proteína bcl-2.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
DE60205872D1 (de) Oxindolderivate als cdk-1 inhibitoren und deren verwendung in therapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee